[Trimetazidine in complex therapy of acute myocardial infarction at the background of diabetes mellitus type 2.].
Patients (n=52) with acute myocardial infarction (MI) and diabetes mellitus type 2 older than 18 years were distributed within first 24 hours of MI into 2 groups. In patients of group 1 (n=28) standard therapy was supplemented with trimetazidine (70 mg/day) for 30 days, patients of group 2 received only standard therapy. The following parameters were assessed: rate of recurrent MIs, inhospital mortality, dynamics of MB CR, rate of development and progression of heart failure, dynamics of brain natriuretic peptide, parameters of echocardiogram. Mortality in group 1 at the background of thrombolytic therapy (TLT) was 5.9% (n=1) what was significantly lower than in group 2 where this parameter was equal to 35.7% (n=5), p=0.006. A tendency was noted to lowering of rate of recurrent MIs (17.6 and 21.4% in groups 1 and 2, respectively). Analogous parameters did not differ significantly between subgroups of patients not treated with TLT. In group 1 significant 31% lowering of MB CK level was noted in TLT treated patients. In group 2 level of MB CK after 27-30 hours significantly increased by 30.16% compared with initial level (p=0.001). At analysis of analogous parameters in subgroups not treated with TLT significant differences were not obtained. There were no significant differences between groups according to echocardiography data, however ejection fraction in group 1 was 12.6% higher than in group 2 (p>0.05).
Moscow State medical Dental University; ul. Delegatskaya, 20, 103473 Moscow, Russia; Russian Medical University; ul. Ostrovityanova, 1, 117437 Moscow, Russia.
S N
SN
Tereshchenko
A V
AV
Golubev
I V
IV
Kositsyna
N A
NA
Dzhaiani
A G
AG
Kochetov
D000208:Acute Disease; D004452:Echocardiography; D006801:Humans; D009203:Myocardial Infarction / Q000628:therapy; D020097:Natriuretic Peptide, Brain; D014292:Trimetazidine
D020097:Natriuretic Peptide, Brain; D014292:Trimetazidine